drugset / Trial / NCT05541627
A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 (previously BV-101) in Adults with Early Manifest Huntington's Disease
Timeline
- Start
- 2022-10-12
- Primary completion
- 2024-04-04
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AB-1001 | Gene therapy (AAV / viral vector) | — | Other |